Growth Metrics

Gilead Sciences (GILD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $4.1 billion.

  • Gilead Sciences' Cash from Operations fell 466.47% to $4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 billion, marking a year-over-year decrease of 354.22%. This contributed to the annual value of $10.8 billion for FY2024, which is 3524.86% up from last year.
  • According to the latest figures from Q3 2025, Gilead Sciences' Cash from Operations is $4.1 billion, which was down 466.47% from $827.0 million recorded in Q2 2025.
  • Over the past 5 years, Gilead Sciences' Cash from Operations peaked at $4.3 billion during Q3 2024, and registered a low of $827.0 million during Q2 2025.
  • Its 5-year average for Cash from Operations is $2.4 billion, with a median of $2.3 billion in 2021.
  • Within the past 5 years, the most significant YoY rise in Gilead Sciences' Cash from Operations was 14552.71% (2024), while the steepest drop was 4332.76% (2024).
  • Gilead Sciences' Cash from Operations (Quarter) stood at $3.2 billion in 2021, then fell by 19.91% to $2.6 billion in 2022, then dropped by 15.5% to $2.2 billion in 2023, then surged by 37.16% to $3.0 billion in 2024, then soared by 38.08% to $4.1 billion in 2025.
  • Its Cash from Operations was $4.1 billion in Q3 2025, compared to $827.0 million in Q2 2025 and $1.8 billion in Q1 2025.